Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN)
India
· Delayed Price · Currency is INR 207.58
+0.29 (0.14%)
Jul 1, 2025, 10:28 AM IST
Nath Bio-Genes (India) Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 3,649 | 3,326 | 3,014 | 2,784 | 3,076 | Upgrade
|
Other Revenue | - | 1.41 | - | - | -0 | Upgrade
|
| 3,649 | 3,328 | 3,014 | 2,784 | 3,076 | Upgrade
| |
Revenue Growth (YoY) | 9.66% | 10.42% | 8.26% | -9.49% | 9.89% | Upgrade
|
Cost of Revenue | 1,355 | 839.27 | 814.33 | 936.65 | 980.14 | Upgrade
|
Gross Profit | 2,294 | 2,488 | 2,199 | 1,847 | 2,095 | Upgrade
|
Selling, General & Admin | 1,495 | 442.1 | 372.48 | 382.11 | 410.98 | Upgrade
|
Other Operating Expenses | 300.87 | 1,546 | 1,338 | 1,088 | 1,013 | Upgrade
|
Operating Expenses | 1,834 | 2,021 | 1,741 | 1,501 | 1,452 | Upgrade
|
Operating Income | 459.82 | 467.47 | 458.79 | 345.7 | 643.36 | Upgrade
|
Interest Expense | -104.84 | -86.29 | -95.73 | -101.25 | -79.02 | Upgrade
|
Interest & Investment Income | - | 3.23 | 0.18 | 10.93 | 12.14 | Upgrade
|
Currency Exchange Gain (Loss) | - | - | 4.3 | 0.59 | -1.23 | Upgrade
|
Other Non Operating Income (Expenses) | 45.46 | -3.26 | -5.93 | -3.88 | -8.45 | Upgrade
|
EBT Excluding Unusual Items | 400.44 | 381.15 | 361.59 | 252.08 | 566.79 | Upgrade
|
Gain (Loss) on Sale of Assets | - | 0.01 | -0.01 | 0.04 | 0.04 | Upgrade
|
Other Unusual Items | - | 34.49 | - | -887.82 | - | Upgrade
|
Pretax Income | 400.44 | 415.65 | 361.64 | -634.34 | 567.51 | Upgrade
|
Income Tax Expense | 19.85 | 19.46 | 11.53 | 39.52 | 10.9 | Upgrade
|
Earnings From Continuing Operations | 380.6 | 396.19 | 350.11 | -673.85 | 556.62 | Upgrade
|
Net Income | 386 | 396.19 | 350.11 | -673.85 | 556.62 | Upgrade
|
Net Income to Common | 386 | 396.19 | 350.11 | -673.85 | 556.62 | Upgrade
|
Net Income Growth | -2.57% | 13.16% | - | - | 10.26% | Upgrade
|
Shares Outstanding (Basic) | 19 | 19 | 19 | 19 | 19 | Upgrade
|
Shares Outstanding (Diluted) | 19 | 19 | 19 | 19 | 19 | Upgrade
|
Shares Change (YoY) | 0.85% | - | - | - | - | Upgrade
|
EPS (Basic) | 20.14 | 20.85 | 18.42 | -35.46 | 29.29 | Upgrade
|
EPS (Diluted) | 20.14 | 20.85 | 18.42 | -35.46 | 29.29 | Upgrade
|
EPS Growth | -3.39% | 13.16% | - | - | 10.26% | Upgrade
|
Free Cash Flow | 96.61 | 478.18 | 354.85 | -39.56 | -104.34 | Upgrade
|
Free Cash Flow Per Share | 5.04 | 25.16 | 18.67 | -2.08 | -5.49 | Upgrade
|
Dividend Per Share | 2.000 | 2.000 | 2.000 | 2.000 | 2.000 | Upgrade
|
Gross Margin | 62.85% | 74.78% | 72.98% | 66.35% | 68.13% | Upgrade
|
Operating Margin | 12.60% | 14.05% | 15.22% | 12.42% | 20.92% | Upgrade
|
Profit Margin | 10.58% | 11.91% | 11.62% | -24.21% | 18.10% | Upgrade
|
Free Cash Flow Margin | 2.65% | 14.37% | 11.77% | -1.42% | -3.39% | Upgrade
|
EBITDA | 497.98 | 499.99 | 488.91 | 376.54 | 671.52 | Upgrade
|
EBITDA Margin | 13.65% | 15.02% | 16.22% | 13.53% | 21.83% | Upgrade
|
D&A For EBITDA | 38.16 | 32.52 | 30.12 | 30.84 | 28.16 | Upgrade
|
EBIT | 459.82 | 467.47 | 458.79 | 345.7 | 643.36 | Upgrade
|
EBIT Margin | 12.60% | 14.05% | 15.22% | 12.42% | 20.92% | Upgrade
|
Effective Tax Rate | 4.96% | 4.68% | 3.19% | - | 1.92% | Upgrade
|
Revenue as Reported | 3,649 | 3,333 | 3,019 | 2,802 | 3,092 | Upgrade
|
Advertising Expenses | - | 50.51 | 37.04 | 16.34 | 19.43 | Upgrade
|
Updated Jan 23, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.